Phase I Study of GDC-0941 alone in Patients with Solid Tumors or GDC-0941 in Combination with Carboplatin / Paclitaxel + Bevacizumab in Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Chugai Pharmaceutical Co., Ltd.0 个研究点目标入组 19 人开始时间: 2013年6月14日最近更新: 2023年10月17日

试验速览

暂无简介。

•-Histologically or cytologically confirmed solid tumors.
•-Advanced or recurrent cancer for which standard treatments are ineffectve or are not established.
•-ECOG PS 0 or 1.
•-Histologically or cytologically confirmed Non-squamous Non-small cell lung cancer (NSCLC).
•-Patients with Stage 3B or 4 NSCLC, or postoperative recurrence of NSCLC.
•-No history of chemotherapy for advanced or recurrent NSCLC.
•-ECOG PS 0 or 1.

•Stage 1 and Stage 2
•-Central nerves system metastases accompanying symptoms or requiring treatment.
•-Type 1 or Type 2 Diabetes requiring drug treatment.
•-History of treatment with PI3K inhibitor.
•-Current or previous radiographic evidence of Interstitial Lung Disease.
•-Current or previous hemoptysis or hemosputum.
•-Bleeding tendency.
•-Current radiographic evidence of cavitary lung lesions.
•-Current peripheral neuropathy of Grade >=2.

发起方